Drug Profile
Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical
Alternative Names: Anti-FGF23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; burosumab-twza; Crysvita; KRN 23; UX 023Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer Kyowa Hakko Kirin; Kyowa Kirin; Ultragenyx Pharmaceutical
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Fibroblast growth factor 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Osteomalacia; X-linked dominant hypophosphataemic rickets
- Phase II Nevus
Most Recent Events
- 30 Sep 2023 Registered for Osteomalacia in Serbia (SC) before September 2023 (Kyowa Kirin pipeline, February 2024)
- 30 Sep 2023 Registered for X-linked dominant hypophosphataemic rickets in Serbia (SC) before September 2023 (Kyowa Kirin pipeline, February 2024)
- 30 Sep 2023 Preregistration for Osteomalacia in Macedonia (SC) (prior to September 2023)